key: cord-1052209-6hcvyhqz
authors: Sattler, Laurent; Feugeas, Olivier; Hager, Claire; Grunebaum, Lélia; Desprez, Dominique
title: COVID‐19 in a pediatric patient with Glanzmann thrombasthenia
date: 2020-08-15
journal: Pediatr Blood Cancer
DOI: 10.1002/pbc.28662
sha: bfecf98ad3b29e2e045f9b1a89251f07b5402047
doc_id: 1052209
cord_uid: 6hcvyhqz

nan

To the Editor:

To date, management of coronavirus disease 2019 (COVID-19)associated coagulopathy has been based on interim thromboprophylaxis guidance. Evidence still lacks, especially in constitutional bleeding disorders (CBD) given the additional bleeding tendency. We report here a case of COVID-19 in a young girl with type 1 Glanzmann thrombasthenia (GT).

On March 26, 2020 (day 1), this 16-year old girl presented influenzalike illness with myalgia, headache, dry cough, diarrhea, and 40 • C fever, associated with loss of taste and smell. On day 3, azithromycin was initiated by her regular doctor. Epistaxis and menorrhagia appeared on day 6, with alteration of the patient's general condition requiring hospitalization in a conventional pediatric COVID-19 unit. At admission, oxygen saturation was 97%. Chest radiography revealed an interstitial syndrome. The blood cell count was normal. We noted a bio- 

Assessment of menstrual blood loss using a pictorial chart

Severe bleeding in a patient with factor XIII deficiency and COVID-19

Clinical findings in a patient with haemophilia A affected by COVID-19

Glanzmann thrombasthenia: genetic basis and clinical correlates

The judicious use of recombinant factor VIIa

Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19

COVID-19 and its implications for thrombosis and anticoagulation

In-hospital management of persons with haemophilia and COVID-19: practical guidance

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Coagulopathy of COVID-19 and antiphospholipid antibodies